On November 21, Walvax Biotechnology (300142) announced that the clinical trial application for its Varicella Attenuated Live Vaccine has been accepted by the National Medical Products Administration, with the acceptance number CXSL2500991.

The application was jointly developed by the company and its subsidiary. The product is named Varicella Attenuated Live Vaccine and is classified as a preventive biological product under Category 3.3. The vaccine is produced using an attenuated strain of the varicella-zoster virus and aims to stimulate the body's immune response against the virus to prevent varicella.

The announcement noted that although the clinical trial application for this vaccine has been accepted, it must still be approved by the Center for Drug Evaluation of the National Medical Products Administration after technical review before clinical trials can proceed. The outcome of the review and approval process remains uncertain. This acceptance is not expected to have a significant impact on the company's operating performance for the current year.

In the first three quarters of 2025, Walvax Biotechnology reported revenue of RMB 17.19 billion and a net profit attributable to shareholders of RMB 1.63 billion.

Reference: https://finance.eastmoney.com/a/202511213571547667.html